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Discussion
Dr Joseph Zwischenberger (Lexington, Ky). Dr Bayer, you are
to be congratulated for such a technically challenging approach to
orthotopic lung transplant as well as the use of nanoparticles. The
issue with nanoparticles is that you have to do the pharmacoki-
netics, you have to match the delivery medium with the drug
you are intending to deliver, and then you have to make sure it
gets to the right place.
I am concerned about a couple things. First of all, you showed a
distinct split between the dose delivery in the 4 rats that seemed to
take on the drug and the 2 that did not. I would like to hear you
comment, first of all, on how they were able to inhale the agent.
You mentioned that they were inhaled, but you did not tell us
how or the circumstances or how you would control the dosimetry.
The second question is, you only used 6 animals in each group,
and because only 4 got the drug, we really did a study on 4 rats.
I am concerned that we did not have a large enough N. Lastly,
we are all judged on lung transplantation at 1-year and 3-year sur-
vivals, and yet this study only went 4 hours.
I would like to hear your responses to those, please.
Dr Bayer. To your first question about the delivery of the drug,
in a pharmacokinetic study that had been done previously, wewere
able to show adequate delivery of the drug to the rats. One of the
problems is that the rat is placed into a nose-only chamber and this
is connected to an Aeroneb nebulizer (Aerogen, Galway, Ireland)
where the medication gets aerosolized and the rat breathes sponta-
neously. Things that could affect the drug delivery are if the rat has
rapid breathing or anxiety, there could be unequal delivery into theThe Journal of Thoracic and Carlungs; some of the drug could be deposited into the main airway
and not go all theway into the lower airways; and if they have rapid
breathing, the drug could be eliminated faster. I think in future
studies we might need to test administering the drug while the
rats are endotracheally intubated and mechanically ventilated
and we might have a more uniform delivery of the drug.
Your question about the N, prior to the study, when we were
doing our proposal, we had a power calculation done by our statis-
tics department. They suggested that an N of 6 should be appro-
priate to see a treatment effect. We did not anticipate that 2 rats
would have lower tacrolimus levels compared with the rest of
them. Now, reviewing our results we might have needed a higher
N in the beginning to show a beneficial effect of the medication.
Dr Zwischenberger. And the 4 hours?
Dr Bayer. We wanted to look at early changes after ischemia-
reperfusion injury. We know that within a few hours after reperfu-
sion that there is already an abundant amount of release of inflam-
matory cytokines and influx of neutrophils, T-cells, and
macrophages into the graft. Other studies that we looked at before
the start of our experiments used a similar reperfusion time of 4
hours and were able to show an effect on the ischemia reperfusion
injury with pretreatment of tacrolimus.
Dr Zwischenberger. So you have hit upon a very important
point and that is that the delivery of nanoparticles is very depen-
dent on how slowly and how deeply the recipient breathes and
how it is delivered. I look forward to when you train your rats to
breathe slow and deep.
Dr Frank D’Ovidio (New York, NY). I have a couple of ques-
tions. What was the preservation solution that you used for the
lungs?
Dr Bayer.We did not preserve the lungs. We used fresh lung for
our flow cytometry analysis, and then the lung was frozen for the
rest of the analysis.
Dr D’Ovidio. No, I mean during the ischemic period of time.
Did you flush the lungs?
Dr Bayer. When the lungs were harvested, we flushed them
with the preservation solution Perfadex (Xvivo, G€oteborg,
Sweden), and then they were stored in an inflated state on ice.
Dr D’Ovidio. I probably missed it throughout the presentation.
Why did you have to use lactose as a vehicle?
Dr Bayer. Lactose was chosen because it is well tolerated,
easily absorbed, and it is thought to help with the absorption of
the tacrolimus, which is by nature a lipophilic drug.
Dr D’Ovidio. Along that line, did you try a group of rats where
you just used normal saline and see what the inflammatory
response is from delivering lactose?
Dr Bayer. I’m sorry, could you please explain your question?
Dr D’Ovidio. Did you test the lactose per se versus a control
group of normal saline?
Dr Bayer. No, we have not done that. That would be something
we could include in a future study.
Dr D’Ovidio. I would suggest you do it, because a 3-hour
ischemic time in a rat model historically would give much better
PO2s, and I wonder if the lactose per se is giving you an inflamma-
tory process. I would double-check for that. I worked with amodel,
and to get the model to work, we would have to implement 18
hours of cold ischemia to show the difference in PO2s.diovascular Surgery c Volume 146, Number 5 1219
